在多发性骨髓瘤患者中,CYP2C19多态性对基于博特佐米布的治疗反应的影响
Lavisha Goel1, Pooja Gupta1, Lalit Kumar2
1Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 110029, India.
在多发性骨髓瘤患者中,CYP2C19遗传变异会影响博特佐米布的有效性. 了解这些遗传差异可以个性化治疗,并可能减少外围神经病变等副作用.
科学领域:
- 药物遗传学 药物遗传学
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 博尔特佐米布 (Bortezomib) 是一种主要的抗髓瘤药物,由肝酶代谢.
- CYP2C19酶活性可能是多态的,这可能解释了一些患者的治疗不响应.
- 药物代谢酶的遗传变异越来越被认为是个性化医学的关键.
研究的目的:
- 为了研究CYP2C19基因多态化与多发性骨髓瘤患者接受博雷佐米布治疗的治疗反应之间的关联.
- 探索CYP2C19基因型与外围神经病变的发生率之间的关系,这是博特佐米布常见的副作用.
主要方法:
- 使用聚合酶连锁反应-限制片段长度多态的CYP2C19 *2, *3和 *17等位基因的基因定型.
- 招募220名未经治疗的多发性骨髓瘤患者,接受基于博特佐米布的诱导疗法.
- 使用CTCAE标准v5.0.0.的边缘神经病变的监测和分级.
主要成果:
- 在38.6% (*2),2.3% (*3) 和23.7% (*17) 的患者中存在CYP2C19多态性.
- 在治疗响应者和不响应者之间观察到CYP2C19*2等位基因频率的显著差异 (p=0.02).
- 所有广泛代谢者 (n=54) 均对治疗有反应,而 *2/*2 或 *3/*3 基因型患者的外围神经病变不太常见.
结论:
- CYP2C19酶多态性显著影响多发性骨髓瘤中博特佐米布治疗反应.
- 对CYP2C19的药物遗传学分析可能有助于优化博特佐米布治疗和管理外围神经病变.
- 这项研究强调了药物遗传学在多发性骨髓瘤个性化治疗策略中的潜力.
更多相关视频
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Drug Response: Overview
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
